Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley Cuts JD HEALTH's TP to HKD66, Lowers EPS Forecast
Recommend 5 Positive 5 Negative 3 |
||||
|
||||
|
After factoring in JD HEALTH (06618.HK)'s 2025 results data, Morgan Stanley has raised its 2026-28 revenue forecasts for JD HEALTH (06618.HK) by 5%/ 6%/ 7% to reflect the continued growth momentum in online pharmaceutical sales. In Morgan Stanley's estimate, JD HEALTH's 2026 revenue growth will rise by 18%, in which pharmaceutical sales, non-pharmaceutical sales, and service income will increase by 25%, 12%, and 19% YoY. In terms of earnings, Morgan Stanley predicts JD HEALTH's 2026 adjusted operating profit to remain flat. It has cut the 2026-28 adjusted EPS forecasts by 4%/ 5%/ 6%. Morgan Stanley's target price for JD HEALTH has fallen from HKD70 to HKD66. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
